Chapter Information
Students in the Department of Pharmacological and Pharmaceutical Sciences established the AAPS-University of Houston (UH) Student Chapter in November 2004. Specific chapter objectives include:
- Expand the chapter member base by communicating its
significance to students from the bioengineering and basic
sciences departments.
- Establish the chapter as the basis of interaction between
students and pharmaceutical scientists from academia,
government and industry, to help students gain insight into
these fields and realize their career objectives.
- Make the members aware of the latest developments in the
pharmaceutical sciences by inviting speakers and organizing
symposia/meetings.
- Organize mock interview sessions with the UH Career
Development Center and post job openings and internship
opportunities available to students.
- Increase the participation of students at national meetings
and local meetings, such as the Southern Regional Discussion
Group, and be a host of future events.
- Organize social gatherings for UH students and faculty so
the chapter serves as a professional and educational
experience, as well as a platform for social interaction.
Activities
2004-2005
February 8, 2005
Nanotechnology approaches to medicine:
Dr. Ananth Annapragada, University of Texas HSC
February 18, 2005
New Drug Application (NDA)
Abbreviated NDA (ANDA)
(Live Video conference):
Ms. Kim Colangelo, FDA
Diffusion phenomenon and implantable delivery systems:
Dr. Jaymin Shah, Pfizer Global R& D
February 25, 2005
ICH, SUPAC
FDA Inspection and Audit
Post approval responsibility:
Mr. Ravi Chivukula, Johnson & Johnson Pharmaceutical R&D
March 11
U.S. and International Requirements for Globalization:
Dr. Sasima Phadungpojna, Cephalon
Nutraceuticals, herbal products and cosmetic products developments:
Dr. Sasima Phadungpojna,Cephalon
March 25
Liposomal drug delivery:
Dr. Dong Liang, Texas Southern Univ.
April 1
Delivery systems with biodegradable polymers
Dr. Chun Li, M.D. Anderson Cancer Center
April 8
Formulation and delivery of biotechnological Products
Dr. John Wang, Genetech
Bioavailability/Bioequivalence (BA/BE)
Dr. Kofi Kumi, FDA
April 22
Drug-Drug Interaction in Drug Development
Dr. Robert Kumi, FDA
April 29
Exposure-Safety Information Guided Dosage Form and Dose Regimen Selections
Dr. Johnny Lau, FDA
Pulmonary delivery systems
Dr. Ananth Annapragada, University of Texas HSC
|
